Literature DB >> 34879977

IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045.

Hong Sun1, Pouya Saeedi1, Suvi Karuranga1, Moritz Pinkepank1, Katherine Ogurtsova2, Bruce B Duncan3, Caroline Stein3, Abdul Basit4, Juliana C N Chan5, Jean Claude Mbanya6, Meda E Pavkov7, Ambady Ramachandaran8, Sarah H Wild9, Steven James10, William H Herman11, Ping Zhang7, Christian Bommer12, Shihchen Kuo13, Edward J Boyko14, Dianna J Magliano15.   

Abstract

AIMS: To provide global, regional, and country-level estimates of diabetes prevalence and health expenditures for 2021 and projections for 2045.
METHODS: A total of 219 data sources meeting pre-established quality criteria reporting research conducted between 2005 and 2020 and representing 215 countries and territories were identified. For countries without data meeting quality criteria, estimates were extrapolated from countries with similar economies, ethnicity, geography and language. Logistic regression was used to generate smoothed age-specific diabetes prevalence estimates. Diabetes-related health expenditures were estimated using an attributable fraction method. The 2021 diabetes prevalence estimates were applied to population estimates for 2045 to project future prevalence.
RESULTS: The global diabetes prevalence in 20-79 year olds in 2021 was estimated to be 10.5% (536.6 million people), rising to 12.2% (783.2 million) in 2045. Diabetes prevalence was similar in men and women and was highest in those aged 75-79 years. Prevalence (in 2021) was estimated to be higher in urban (12.1%) than rural (8.3%) areas, and in high-income (11.1%) compared to low-income countries (5.5%). The greatest relative increase in the prevalence of diabetes between 2021 and 2045 is expected to occur in middle-income countries (21.1%) compared to high- (12.2%) and low-income (11.9%) countries. Global diabetes-related health expenditures were estimated at 966 billion USD in 2021, and are projected to reach 1,054 billion USD by 2045.
CONCLUSIONS: Just over half a billion people are living with diabetes worldwide which means that over 10.5% of the world's adult population now have this condition.
Copyright © 2021. Published by Elsevier B.V.

Entities:  

Keywords:  Diabetes; Epidemiology; Health economics; International Diabetes Federation; Prevalence; Projections

Mesh:

Year:  2021        PMID: 34879977     DOI: 10.1016/j.diabres.2021.109119

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  253 in total

1.  Blood Lead Level Is Associated with Visceral Adipose Dysfunction in Patients with Type 2 Diabetes.

Authors:  Chi Chen; Bin Wang; Haojie Zhang; Yuying Wang; Shiyan Yu; Shuo Zhou; Yi Chen; Fangzhen Xia; Hualing Zhai; Ningjian Wang; Yingli Lu
Journal:  Biol Trace Elem Res       Date:  2022-07-18       Impact factor: 4.081

Review 2.  Epigenetic modifications in metabolic memory: What are the memories, and can we erase them?

Authors:  Zhuo Chen; Rama Natarajan
Journal:  Am J Physiol Cell Physiol       Date:  2022-07-04       Impact factor: 5.282

3.  The Effect of Electroacupuncture Preconditioning on Regional Cerebral Oxygen Saturation Levels in Elderly Patients with Diabetes.

Authors:  Jia-Qi Ning; Jian-Sheng Luo; Ling-Ling Ding; Yu-Hong Guo; Zhuo-Ya Chen; Qi Wang; Rui-Ling Zhou
Journal:  Diabetes Metab Syndr Obes       Date:  2022-07-21       Impact factor: 3.249

Review 4.  The gut microbiome as possible mediator of the beneficial effects of very low calorie ketogenic diet on type 2 diabetes and obesity: a narrative review.

Authors:  G Defeudis; M Rossini; Y M Khazrai; A M V Pipicelli; G Brucoli; M Veneziano; F Strollo; A Bellia; O Bitterman; D Lauro; D Mora; E Santarelli
Journal:  Eat Weight Disord       Date:  2022-07-01       Impact factor: 3.008

5.  Diabetes and its Complications.

Authors:  Simon Matoori
Journal:  ACS Pharmacol Transl Sci       Date:  2022-07-12

Review 6.  The effects of probiotic and synbiotic supplementation on inflammation, oxidative stress, and circulating adiponectin and leptin concentration in subjects with prediabetes and type 2 diabetes mellitus: a GRADE-assessed systematic review, meta-analysis, and meta-regression of randomized clinical trials.

Authors:  Kaveh Naseri; Saeede Saadati; Farahnaz Ghaemi; Damoon Ashtary-Larky; Omid Asbaghi; Amir Sadeghi; Reza Afrisham; Barbora de Courten
Journal:  Eur J Nutr       Date:  2022-10-14       Impact factor: 4.865

7.  Sorafenib decreases glycemia by impairing hepatic glucose metabolism.

Authors:  Jingjing Ma; Fang Sui; Yan Liu; Mengmeng Yuan; Hui Dang; Rui Liu; Bingyin Shi; Peng Hou
Journal:  Endocrine       Date:  2022-10-07       Impact factor: 3.925

8.  A 5-year trend in the use of sodium-glucose co-transporter 2 inhibitors and other oral antidiabetic drugs in a Middle Eastern country.

Authors:  Nancy Zaghloul; Ahmed Awaisu; Ahmed Mahfouz; Sumaya Alyafei; Hazem Elewa
Journal:  Int J Clin Pharm       Date:  2022-09-28

Review 9.  On the Verge of Precision Medicine in Diabetes.

Authors:  Josephine H Li; Jose C Florez
Journal:  Drugs       Date:  2022-09-19       Impact factor: 11.431

Review 10.  Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Authors:  Melanie J Davies; Vanita R Aroda; Billy S Collins; Robert A Gabbay; Jennifer Green; Nisa M Maruthur; Sylvia E Rosas; Stefano Del Prato; Chantal Mathieu; Geltrude Mingrone; Peter Rossing; Tsvetalina Tankova; Apostolos Tsapas; John B Buse
Journal:  Diabetologia       Date:  2022-09-24       Impact factor: 10.460

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.